Targeted therapies for brain tumors: will they ever deliver?
MA Vogelbaum - Clinical Cancer Research, 2018 - aacrjournals.org
Clinical Cancer Research, 2018•aacrjournals.org
The strategy of using biologically targeted therapeutics for cancer has yet to translate into
effective treatment of gliomas. The neuro-oncology community is beginning to recognize that
phase 0 studies should be performed to account for the impact of the blood–brain barrier on
the ability of a therapeutic to reach its target (s). Clin Cancer Res; 24 (16); 3790–1.© 2018
AACR. See related article by Sanai et al., p. 3820
effective treatment of gliomas. The neuro-oncology community is beginning to recognize that
phase 0 studies should be performed to account for the impact of the blood–brain barrier on
the ability of a therapeutic to reach its target (s). Clin Cancer Res; 24 (16); 3790–1.© 2018
AACR. See related article by Sanai et al., p. 3820
Abstract
The strategy of using biologically targeted therapeutics for cancer has yet to translate into effective treatment of gliomas. The neuro-oncology community is beginning to recognize that phase 0 studies should be performed to account for the impact of the blood–brain barrier on the ability of a therapeutic to reach its target(s). Clin Cancer Res; 24(16); 3790–1. ©2018 AACR.
See related article by Sanai et al., p. 3820
aacrjournals.org
